oxamoran 875 mg/125 mg filmtabletta
ranbaxy uk ltd. - egyesülnek -
enhancin 375 mg filmtabletta
labormed pharma s.a. - egyesülnek -
enhancin 625 mg filmtabletta
labormed pharma s.a. - egyesülnek -
enhancin 156 mg por belsőleges szuszpenzióhoz
labormed pharma s.a. - egyesülnek -
enhancin 312 mg por belsőleges szuszpenzióhoz
labormed pharma s.a. - egyesülnek -
enhancin 156 mg szuszpenzió
ranbaxy uk ltd. -
enhancin 312 mg szuszpenzió
ranbaxy uk ltd. -
tysabri
biogen netherlands b.v. - natalizumabot - szklerózis multiplex - szelektív immunszuppresszánsok - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 és 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
lumeblue (previously known as methylthioninium chloride cosmo)
alfasigma s.p.a. - metil-tionin-klorid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
fingolimod mylan
mylan ireland limited - fingolimod-hidroklorid - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 és 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.